Novo Nordisk lost its patent on semaglutide earlier this year, the active ingredient in so-called GLP-1 drugs used to treat type 2 diabetes and for chronic weight management. Semaglutide is found in both Ozempic and Wegovy, and Canadian authorities have now approved an Indian version.
According to The New York Times, similar versions are now on the way in China, Brazil and South Africa.
